Advised Transferra, a provider of products and services to life science companies engaged in the development of pharmaceutical products, primarily in the lipid nanoparticle field, on its sale to Evonik Industries, a global specialty chemicals group with annual sales in excess of $15 billion dollars. The Transferra acquisition is a strategic addition to Evonik's nutrition & care segment.

Founded in 1991 as a start-up out of the University of British Columbia, Transferra Nanosciences Inc., formerly Northern Lipids Inc., is a contract development and manufacturing organization. Transferra provides products and services to life science companies engaged in the development of pharmaceutical products, primarily in the lipid nanoparticle field.

Evonik Industries, headquartered in Essen, Germany, is a global specialty chemicals group with annual sales in excess of $15 billion dollars. Evonik has three operating segments - nutrition & care, resource e_x001E_ciency and performance materials. The Transferra acquisition is a strategic addition to their nutrition & care segment.